Clinical experience with a protease inhibitor [N,N-dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy)-phenylacetate] methanesulfate for prevention of recurrence of carcinoma of the mouth and in treatment of terminal carcinoma.
A protease inhibitor, (N,N-dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy)-phenylacetate) methanesulfate was administered orally 3 times daily to 9 patients with squamous cell carcinoma of the oral cavity, at doses ranging from 0.6 g. to 7.2 g. Seven of 9 patients who had undergone all kinds of therapies were observed to see whether recurrence was prevented and in no case did the tumour recur. Also, in 2 terminal secondary cases tumour remission resulted. Histologically, after this therapy, carcinomatous lesions showed marked hyperkeratosis in 2 cases and the survival time in 1 case was markedly prolonged. Haematological and gastrointestinal toxicity was almost never observed at these doses.
D000328:Adult; D002294:Carcinoma, Squamous Cell / Q000517:prevention & control* / Q000628:therapy; D004952:Esters; D005069:Evaluation Studies as Topic; D005260:Female; D016670:Gabexate / Q000031:analogs & derivatives*; D006146:Guanidines / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000517:prevention & control* / Q000628:therapy; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D011480:Protease Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*
D004952:Esters; D006146:Guanidines; D011480:Protease Inhibitors; C034532:camostat; D016670:Gabexate